Vedea Healthware

3 to 5% of the population suffers from amblyopia, commonly known as "lazy eye". It's a vision disorder where one eye fails to develop normal vision during childhood. Vedea develops a novel child-friendly treatment for children for ages 5 to 10, leveraging this crucial developmental phase for maximum effectiveness. An effective therapy is extremely important because amblyopia can lead to permanent reduced visual acuity if not treated early. It is crucial to prevent long-term vision impairment and associated societal impacts, ensuring optimal visual function and quality of life for affected individuals. Societal impact includes potential educational and career limitations, as well as implications for healthcare resources and economic productivity.